



# **30<sup>th</sup> Annual Scientific Congress Hong Kong College of Cardiology**

8–10 July 2022 (Fri to Sun) Hong Kong Convention and Exhibition Centre

# **Final Announcement**



The Journal of the Hong Kong College of Cardiology has been revamped and gone online with open access! Submit your work and get published at www.ihkcc.com.hk/journal/



For more information, please visit our website www.hkccasc.com



https://bit.ly/3h0bku9

# WELCOME MESSAGE

Time passes swiftly. It is both astonishing and exciting that the Hong Kong College of Cardiology is stepping into her 30<sup>th</sup> Anniversary of establishment! As the educational program in cardiovascular medicine with the largest scale in Hong Kong, the 30<sup>th</sup> Annual Scientific Congress of the Hong Kong College of Cardiology will be held on 8 – 10 July 2022 at the Hong Kong Convention and Exhibition Centre. This is going to be a hybrid scientific conference with both online and physical participation.

Our Annual Scientific Congress has established herself as the iconic and flagship educational program for cardiovascular professionals from different disciplines in Hong Kong. The Annual Scientific Congress with a rich scientific program was successfully held and well received last year and we recorded a record-high number of over 2,400 registrants and 1,900 attendees from Hong Kong, mainland China and other parts of the world. The Organizing Committee is working with much effort in putting together a highly educational program via different teaching platforms and learning modes. The well-received program components of theme-based symposia, joint sessions with international cardiac societies, Hong Kong Heart Foundation Lecture, abstract and case presentations, poster presentations, Cardiology Course for Family Physicians and General Practitioners, Cardiovascular Therapeutic Workshops, Paediatric Cardiology Program and Allied Cardiovascular Health Professional will continue to be included. To celebrate the 30<sup>th</sup> Anniversary, the HKCC 30<sup>th</sup> Anniversary Keynote Lecture cum Presidential Forum is a must-attend session!

Although we are still amidst the COVID pandemic, we will keep on striving for professional excellence in the management of our patients and continuous learning is doubtlessly the key to this end!



Dr. Ngai-yin Chan

Chairman, Organizing Committee 30<sup>th</sup> Annual Scientific Congress

Immediate Past President, Hong Kong College of Cardiology

# **ORGANIZING COMMITTEE**

#### Chairman

Dr. Ngai-yin Chan

#### Advisors

Dr. Chung-seung Chiang Dr. Patrick Tak-him Ko

Dr. Yuk-kong Lau

#### Co-chairs

Dr. Carmen Wing-sze Chan

Dr. Kin-lam Tsui

Prof. Bryan Ping-yen Yan

#### **Committee Members**

Dr. William Chi-kin Chan Dr. Jason Leung-kwai Chan

Dr. Andy Wai-kwong Chan Dr. Robin Hay-son Chen Dr. Raymond Chi-yan Fung

Dr. Kwok-lun Lee Dr. David Ka-yip Lo Dr. Thomas Tunggal Dr. Michael Ka-lam Wong Dr. Tak-cheung Yung



#### INTERNATIONAL FACULTY-

#### **ACC** Representatives

#### Dr. Roxana Mehran

The Mount Sinai Hospital, United States

#### Dr. Hadley Wilson

Sanger Heart & Vascular Institute, United States

#### **APSC Representatives**

#### Prof. Junya Ako

Kitasato University, Japan

#### Prof. Khung Keong Yeo

National Heart Centre Singapore. Sinaapore

#### **BCOS Representatives**

#### Dr. Charlotte Manisty

University College Hospitals, London, United Kinadom

#### Dr. Chris Plummer

Newcastle's Freeman Hospital. United Kingdom

#### Prof. Stuart Rosen

Imperial College London, United Kinadom

#### **ESC Representatives**

### Prof. Stephan Achenbach

University of Erlangen, Germany

#### Prof. Marco Roffi

University Hospital of Geneva, Switzerland

#### KSC Representatives

#### Prof. Hui Nam Pak

Yonsei University, Korea

#### Prof. Seung Jung Park

Sungkyunkwan University, Korea

#### Dr. David Matthew Biko

Children's Hospital of Philadelphia. **United States** 

#### Prof. Dr. Michael Böhm

University of the Saarland, Homburg/Saar, Germany

#### Prof. Javed Butler

The University of Mississippi, United States

#### Prof. Peter Collins

Imperial College London, United Kingdom

#### Dr. Yoav Dori

Children's Hospital of Philadelphia, **United States** 

#### Prof. Michael Farkouh

University of Toronto, Canada

#### Prof. Ben Freedman

Heart Research Institute, Australia

#### Prof. Saebeom Hur

Seoul National University Hospital, Korea

#### Dr. Michael Katcher

Salem Hospital, Oregon, United

#### Dr. Daniel Knight

Royal Free London NHS Foundation Trust, United Kingdom

#### Dr. Houng Bang Liew

Hospital Queen Elizabeth II. Malavsia

#### Prof. Peter Liu

University of Ottawa Heart Institute, Canada

#### Prof. Raiiv Mahaian

University of Adelaide, Australia

#### Dr. Lisa Mielniczuk

University of Ottawa, Canada

#### Assoc. Prof. Dr. Harry Mond

University of Melbourne & Monash University, Australia

#### Dr. Christian Napp

Hannover Medical School, Germany

#### Prof. Stephen Nicholls

Victorian Heart Institute, Australia

#### Prof. Mario Martins Oliveira

Hospital Santa Marta, CHLC, Lisbon, **Portugal** 

### Dr. David Kwang-leng Quek

Pantai Hospital Kuala Lumpur, Malavsia

#### Sir Prof. Shakeel Qureshi

Evelina Children's Hospital, United Kingdom

#### Prof. Kausik Ray

Imperial College London, United Kingdom

#### Prof. Christian Ruff

Brigham and Women's Hospital, United States

#### Dr. Kothandam Sivakumar

Madras Medical Mission Hospital, India

#### Prof. Robert Storey

University of Sheffield, United Kingdom

#### Dr. Muthiah Vaduganathan

Brigham and Women's Hospital, United States

# LOCAL FACULTY (Hong Kong, China)

Dr. Alan Ka-chun Chan Dr. Jacky Kit Chan

Dr. Jaclyn Chi-lin Chan Dr. Kwok-chiu Chan

Dr. Pui-shan Chan

Dr. Yu-ho Chan Dr. Elaine Mo-chee Chau

Ms. Mei-yi Chau Dr. Robin Hay-son Chen Dr. Yuet-wong Cheng Dr. Danny Hoi-fan Chow

Hon. A. Prof. William Chun-

ming Chui Dr. Raymond Chi-yan Fung Dr. Wing-hong Fung Dr. Jo Jo Siu-han Hai

Dr. Ling-ling lp Dr. Kevin Ka-ho Kam

Dr. Jason Kwok-chun Ko

Dr. Partrick Tak-him Ko

Dr. On-hing Kwok Dr. Sit-yee Kwok

Dr. Sze-wah Lai Dr. Ka-on Lam Dr. Simon Cheuna-chi Lam

Dr. Yuk-kong Lau Prof. Alex Pui-wai Lee Dr. Michael Kang-yin Lee Dr. Godwin Tat-chi Leung Dr. Kevin Lim

Dr. David Ka-yip Lo

Dr. Andrew Kei-yan Ng

Prof. Chung-wah Siu Dr. Frankie Chor-cheung Tam

Dr. Guang-ming Tan Dr. Thomas Tunggal Dr. Ivan Man-ho Wong Dr. Michael Ka-lam Wong

Prof. Bryan Ping-yen Yan Prof. Kai-hang Yiu

Dr. Chi-yui Yung



**E-Poster • Virtual Exhibition Available ONLINE** 

All times indicated are Hong Kong Time (UTC +8).
Venue: Meeting Rooms S421-430, Level 4, Hong Kong Convention and Exhibition Centre

8 July 2022 (Fri)				
Room S421 (Virtual Room 1)				
0800-0915	Korean Society of Cardiology @HKCC ASC: Advances in Pacing and Cardiac Electrophysiology			
0915-1015	Oral Abstracts Presentation Best Poster Presentation (0900–0950)			
1045-1215	1045-1215 Best Abstracts Presentation			
1215-1300	EP Lunch Symposium*			
1300-1700	Guidelines and Practice: Clinical Case Based Conference (GAP-CCBC)			
1700-1815	700-1815 Asian Pacific Society of Cardiology @HKCC ASC: Advances in Coronary Intervention			

9 July 202	9 July 2022 (Sat)				
	Room S421 (Virtual Room 1)	Room S423-424 (Virtual Room 2)	Room S426-427 (Virtual Room 3)		
0800-1000	Heart Rhythm Symposium	Diabetes and Cardiovascular Risk Factors Symposium (0820-1000)	Paediatric Cardiology Program: Paediatric Cardiology Symposium I (0825-1030)		
1100-1230	Heart Failure Symposium I	Allied Cardiovascular Health Professional Symposium: Cardiac Manifestations of COVID-19 (1000-1230)	Free Paper Session (Abstract & Interesting Case Presentations) (1100-1300)		
1230-1350	Lunch Symposium*				
1400-1415	Opening Ceremony				
1415-1445	Hong Kong Heart Foundation Lecture		Paediatric Cardiology Program: Paediatric		
1445-1600	HKCC 30 <sup>th</sup> Anniversary Keynote Lecture cum Presidential Forum	Hong Kong Heart Foundation, Dr CO Pun and Dr Mary BL Kwong Scholarship Symposium (1515–1635)	Cardiology Symposium II (1415-1620)		
1630-1745	European Society of Cardiology @HKCC ASC: Controversies in the Management of Coronary Artery Disease		Adult Congenital Heart Disease (ACHD) Symposium (1630-1800)		
1745-1900	Heart Failure Symposium II	Coronary Ischaemia Symposium I (1730-1930)			

10 July 20	)22 (Sun)		
	Room S421 (Virtual Room 1)	Room S423-424 (Virtual Room 2)	Room S426-427 (Virtual Room 3)
0800-0915	Coronary Ischaemia Symposium II	Cardiology Course for Family Physicians and General Practitioners: Session 1 – Preventive	Rooms S426-427 & 428 Cardiovascular Therapeutics
0915-1055	American College of Cardiology @HKCC ASC: Hot Issues in Cardiology	Cardiology: Expanding the Role of GP in Cardiology (0900-1030)	Workshop (0900-1230) (For physical participants
1115-1230	Atrial Fibrillation Symposium	Cardiology Course for Family Physicians and General Practitioners: Session 2 – Cardiology Updates: New Guidelines in Clinical Practice (1100-1230)	only)
1230-1430	Lunch Symposium*		
1430-1630	Best Challenging/Interesting Cardiac Intervention Cases Presentation	Cardiology Course for Family Physicians and General Practitioners: Session 3 – Common Cardiology Challenges in General Practice (1400-1530)	Symposium on Under- recognized Aspects in Cardiovascular Diseases (1400-1500)
1650-1850	Best HKCC-HKPHCA Challenging/ Interesting Clinical Cardiology Cases Presentation	Cardiology Course for Family Physicians and General Practitioners: Session 4 – Cardiology Issues in Women & Paediatrics (1600–1700)	British Cardio-Oncology Society @HKCC ASC: Cardio- oncology in the Era of COVID-19 Pandemic (1600-1805)
1850-1855	Closing Remarks		

Program is subject to change without prior notice.
\*Lunch will be arranged for physical participants who have selected main program during registration. Seats are based on a first-come-first-served basis.



### **MAIN PROGRAM**

# 8 July 2022 (Friday)

Time	Session / Topic / Speaker				
0800-0915	Korean Society of Cardiology @HKCC ASC: Advances in Pacing and Cardiac Electrophysiology				
0800-0825	Al and computational modeling for patient o	and target select	ions of AF ablation	Prof. Hui Nam Pak	
0825-0850	Orthodromic and antidromic snare technique challenging coronary venous anatomy	es for left ventric	ular lead implantation in	Prof. Seung Jung Park	
0850-0915	When CRT is not an option - What's next?			Dr. Jo Jo Siu-han Hai	
0915-1015	Oral Abstracts Presentation	0900-0950	Best Poster Presentation		
1015-1045	Break / Exhibition / E-poster Viewing				
1045-1215	Best Abstracts Presentation				
1215-1300	EP Lunch Symposium				
	TBC   Prof. Rajiv Mahajan   (Sponsored by Abbott Medical)				
1300-1500	Guidelines and Practice: Clinical Case Based Conference (GAP-CCBC) – Part 1				
1500-1700	Guidelines and Practice: Clinical Case Bas	ed Conference (	GAP-CCBC) – Part 2		
1700-1815	Asian Pacific Society of Cardiology @HKCC ASC: Advances in Coronary Intervention				
1700-1725	Early experience with shockwave: Early expe	rience and patie	nt selection	Prof. Khung Keong Yeo	
1725-1750	Treatment of acute coronary syndrome: Who	at is to come?		Prof. Junya Ako	
1750-1815	Shockwave intravascular lithotripsy: The goo	d, the bad and t	he ugly	Dr. On-hing Kwok	

# 9 July 2022 (Saturday)

Time	Session / Topic / Speaker				
0800-1000	Heart Rhythm Symposium	leart Rhythm Symposium		Diabetes and Cardiovascu Factors Symposium	ılar Risk
0800-0830	Heart rhythm monitoring and screening in clinical practice	Assoc. Prof. Dr. Harry Mond	0820-0845	The problem with sweet heart: Role of GLP-1 RA in preventing cardiovascular events in type 2 diabetes (Sponsored by Eli Lily)	Prof. Alex Pui- wai Lee
0830-0900	Recent advancements in screening for atrial fibrillation – Risk prediction, diagnosis and clinical outcomes (Sponsored by Pfizer Corporation)	Prof. Ben Freedman	0845-0910	Oral semaglutide: An evidence based approach to adoption of therapy (Sponsored by Novo Nordisk)	Prof. Michael Farkouh
0900-0930	Novel ventricular arrhythmias detection to manage challenging life-threatening undersensing (Sponsored by Abbott Medical)	Dr. Michael Katcher	0910-0935	Influence of cholesterol level on long-term survival and cardiac events after surgical coronary revascularization	Dr. Kevin Lim
0930-1000	Never ending debate: Rate or rhythm control for AF (Sponsored by Johnson & Johnson)	Dr. Wing-hong Fung	0935-1000	Diabetes: More than just a thromboembolic risk factor in NVAF patients (Sponsored by Bayer HealthCare)	Prof. Christian Ruff
1000-1100	Break / Exhibition / E-poster Viewing				
1100-1230	Heart Failure Symposium I				
1100-1130	Recent advances in the treatment of worsening heart failure (Sponsored by Bayer HealthCare)	Dr. Lisa Mielniczuk			
1130-1200	How to incorporate SGLT2 inhibitors into existing treatment strategies for heart failure? (Sponsored by Boehringer Ingelheim)	Prof. Javed Butler			
1200-1230	Cardiovascular and Renal benefits of ARNI in heart failure (Sponsored by Novartis Pharmaceuticals)	Dr. Muthiah Vaduganathan			



# 9 July 2022 (Saturday) - Cont'd

Time	Session / Topic / Speaker				
1230-1350	Lunch Symposium				
	Putting the new standard of care of HFrEF treatment into practice (Sponsored by AstraZeneca)	Prof. Dr. Michael Böhm			
1400-1415	Opening Ceremony				
1415-1445	Hong Kong Heart Foundation Lecture				
	Risk prediction for adverse cardiovascular events: Experience from precision cardiovascular imaging to the application of big data analytics	Prof. Kai-hang Yiu			
1445-1600	HKCC 30 <sup>th</sup> Anniversary Keynote Lecture cu Forum	ım Presidential	1515-1635	Hong Kong Heart Foundation, Dr CO Pun and Dr Mary BL Kwong Scholarship Symposium	
	Development of cardiovascular medicine and Hong Kong College of Cardiology in 30 years	Dr. Patrick Tak- him Ko HKCC Presidents	1515-1535	Cardio-genetics for heart failure, ready for prime time in HK?	Dr. Chi-yui Yung
1600-1630	Break / Exhibition / E-poster Viewing		1535-1555	The journey beyond	Dr. Guang- ming Tan
1630-1745	European Society of Cardiology @HKCC A Controversies in the Management of Cord Disease		1555-1615	Does clopidogrel as DAPT enough to support PCI in AMI? - A lesson to learn	
1630-1655	The diagnostic workup of chronic coronary artery disease and the implications of the ISCHEMIA trial	Prof. Stephan Achenbach	1615-1635	20 years down the road: What's new in TAVI	Dr. Ivan Man- ho Wong
1655-1720	TBC	Dr. Marco Roffi			
1720-1745	Cruising between bleeding and thrombotic complications after percutaneous coronary intervention in Chinese patients		1730-1930	Coronary Ischaemia Symp	osium I
1745-1900	Heart Failure Symposium II		1730-1750	Evidence-based management of angina (Sponsored by A. Menarini)	Prof. Peter Collins
1745-1810	Digital solutions to identify worsening heart failure (Sponsored by Medtronic)	Prof. Mario Martins Oliveira	1750-1810	PCSK9 inhibition in myocardial infarction patients: Beyond LDL-C lowering (Sponsored by Amgen)	Prof. Stephen Nicholls
1810-1835	Is there still any role of early heart rate control under the new and personalized HF management era? (Sponsored by Servier)	Prof. Peter Liu	1810-1830	Frontiers in ACS management - Moving towards individualized antithrombotic therapy (Sponsored by AstraZeneca)	Prof. Robert Storey
1835-1900	Iron deficiency in heart failure: Clinical significance and treatment (Sponsored by Zuellig Pharma)	Dr. Godwin Tat- chi Leung	1830-1850	Impella patient selection and therapy escalation to ECPELLA – When & how (Sponsored by ABIOMED)	Dr. Christian Napp
			1850-1910	What is the next beyond DES? A novel "uncaging" platform for coronary revascularization (Sponsored by Elixir Medical)	Dr. Jaclyn Chi-lin Chan
			1910-1930	TBC (Sponsored by Abbott Medical)	TBC



# 10 July 2022 (Sunday)

Time	Session / Topic / Speaker				
0800-0915	Coronary Ischaemia Symposium II				
	Sustained Limus Release (SLR) drug-	Dr. Houna			
	eluting balloon: The new paradigm				
	for complex PCI				
	(Sponsored by OrbusNeich Medical)				
0825-0850	Insights from guidelines to real world	Dr David			
0025 0050	practice: Individualized approach	Kwang-leng			
	for angina management	Quek			
		Quek			
0050 0015	(Sponsored by Servier)	5 ( 0)			
0850-0915	Vascular effects of PCSK9i in acute	Prof. Chung-			
	myocardial infarction	wah Siu			
	(Sponsored by Sanofi)				
0915-1055	American College of Cardiology @l	HKCC ASC:			
	Hot Issues in Cardiology				
0915-0940	Facing the inevitable: Addressing	Dr. Hadley			
	the international crisis and physician				
	burnout				
0940-1005	Antiplatelet therapy in high bleeding	Dr Povana			
0740 1003		Mehran			
100F 1070	risk patients: Latest evidence				
1005-1030	Robotic PCI: Combining skill &	Dr. Michael			
1000 1000	technology for the future	Kang-yin Lee			
1030-1055	Endovascular interventions for	Prof. Bryan			
	severe manifestations of venous	Ping-yen			
	thromboembolism: Our Hong Kong	Yan			
	experience				
1055-1115	Break / Exhibition / E-poster Viewing	1			
1115-1230	Atrial Fibrillation Symposium	,			
1115-1140	Comparative effectiveness of	Prof. Alex			
1113-1140		Pui-wai Lee			
	oral anticoagulants in everyday	Pui-wai Lee			
	practice: Worldwide and Local data				
	(Sponsored by Boehringer Ingelheim)				
1140-1205	Managing elderly patients with	Dr. Kevin Ka-			
	atrial fibrillation-evidence from	ho Kam			
	RCT's and observational data				
	(Sponsored by Daiichi Sankyo)				
1205-1230	Persistent AF Treatment – PVI and	Dr. Yuet-			
	Beyond	wong Cheng			
	(Sponsored by Johnson & Johnson)				
1230-1430	(Sponsored by Johnson & Johnson)				
1230-1430	Lunch Symposium	Prof Vausik	1/.00-1500	Symposium on Under-recognized Asp	acts in
1230-1430	Lunch Symposium  How does innovation transform the	Prof. Kausik	1400-1500	Symposium on Under-recognized Aspo	ects in
1230-1430	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with			Cardiovascular Diseases	
1230-1430	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with ASCVD?		<b>1400-1500</b> 1400-1430	Cardiovascular Diseases Holistic pulmonary arterial hypertension	Dr. Daniel
1230-1430	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with ASCVD?  (Sponsored by Novartis			Cardiovascular Diseases Holistic pulmonary arterial hypertension management - Best practice from a	
1230-1430	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with ASCVD?			Cardiovascular Diseases  Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre	Dr. Daniel Knight
	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with ASCVD? (Sponsored by Novartis Pharmaceuticals)	Ray	1400-1430	Cardiovascular Diseases Holistic pulmonary arterial hypertension management - Best practice from a	Dr. Daniel Knight
1230-1430 1430-1630	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with ASCVD? (Sponsored by Novartis Pharmaceuticals)	Ray		Cardiovascular Diseases Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen)	Dr. Daniel Knight
	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with ASCVD?  (Sponsored by Novartis	Ray	1400-1430	Cardiovascular Diseases  Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre	Dr. Daniel Knight Dr. Pui-
	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with ASCVD?  (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Cardi	Ray	1400-1430	Cardiovascular Diseases  Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen) How shall we manage hyperuricaemia in patients with cardiovascular	Dr. Daniel Knight Dr. Pui-
	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with ASCVD?  (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Cardi	Ray	1400-1430	Cardiovascular Diseases Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen) How shall we manage hyperuricaemia in patients with cardiovascular comorbidities?	Dr. Daniel Knight Dr. Pui-
	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with ASCVD?  (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Cardi	Ray	1400-1430 1430-1500	Cardiovascular Diseases Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen) How shall we manage hyperuricaemia in patients with cardiovascular comorbidities? (Sponsored by Astellas Pharma)	Dr. Daniel Knight Dr. Pui-
	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with ASCVD?  (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Cardi	Ray	1400-1430 1430-1500 1530-1600	Cardiovascular Diseases  Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen)  How shall we manage hyperuricaemia in patients with cardiovascular comorbidities? (Sponsored by Astellas Pharma)  Break / Exhibition / E-poster Viewing	Dr. Daniel Knight Dr. Pui- shan Chan
	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with ASCVD?  (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Cardi	Ray	1400-1430 1430-1500	Cardiovascular Diseases Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen) How shall we manage hyperuricaemia in patients with cardiovascular comorbidities? (Sponsored by Astellas Pharma) Break / Exhibition / E-poster Viewing British Cardio-Oncology Society @HKC	Dr. Daniel Knight  Dr. Pui- shan Chan
1430-1630	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with ASCVD? (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Card Intervention Cases Presentation	Ray	1430-1500 1430-1600 1600-1805	Cardiovascular Diseases Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen) How shall we manage hyperuricaemia in patients with cardiovascular comorbidities? (Sponsored by Astellas Pharma) Break / Exhibition / E-poster Viewing British Cardio-Oncology Society @HKC Cardio-oncology in the Era of COVID-	Dr. Daniel Knight  Dr. Pui- shan Chan  CC ASC:
	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with ASCVD?  (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Cardi	Ray	1400-1430 1430-1500 1530-1600	Cardiovascular Diseases  Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen) How shall we manage hyperuricaemia in patients with cardiovascular comorbidities? (Sponsored by Astellas Pharma) Break / Exhibition / E-poster Viewing British Cardio-Oncology Society @HKC Cardio-oncology in the Era of COVID- Best practice for Cardio-Oncology	Dr. Daniel Knight  Dr. Pui- shan Chan  CC ASC: 19 Pandemia
1430-1630	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with ASCVD? (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Card Intervention Cases Presentation	Ray	1430-1500 1430-1600 1600-1805	Cardiovascular Diseases  Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen) How shall we manage hyperuricaemia in patients with cardiovascular comorbidities? (Sponsored by Astellas Pharma) Break / Exhibition / E-poster Viewing British Cardio-Oncology Society @HKC Cardio-oncology in the Era of COVID- Best practice for Cardio-oncology patients in the era of COVID-19: Vaccine,	Dr. Daniel Knight  Dr. Pui- shan Chan  CC ASC: 19 Pandemia
1430-1630	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with ASCVD? (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Card Intervention Cases Presentation	Ray	1430-1500 1430-1500 1530-1600 1600-1805	Cardiovascular Diseases Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen) How shall we manage hyperuricaemia in patients with cardiovascular comorbidities? (Sponsored by Astellas Pharma) Break / Exhibition / E-poster Viewing British Cardio-Oncology Society @HKC Cardio-oncology in the Era of COVID-Best practice for Cardio-oncology patients in the era of COVID-19: Vaccine, treatment, tele-health and more	Dr. Daniel Knight  Dr. Pui- shan Chan  CC ASC: 19 Pandemic Prof. Stuart Rosen
1430-1630	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with ASCVD? (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Card Intervention Cases Presentation	Ray	1430-1500 1430-1600 1600-1805	Cardiovascular Diseases  Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen) How shall we manage hyperuricaemia in patients with cardiovascular comorbidities? (Sponsored by Astellas Pharma) Break / Exhibition / E-poster Viewing British Cardio-Oncology Society @HKC Cardio-oncology in the Era of COVID- Best practice for Cardio-oncology patients in the era of COVID-19: Vaccine,	Dr. Daniel Knight  Dr. Pui- shan Chan  CC ASC: 19 Pandemia
1430-1630	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with ASCVD? (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Card Intervention Cases Presentation	Ray	1430-1500 1430-1500 1530-1600 1600-1805	Cardiovascular Diseases Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen) How shall we manage hyperuricaemia in patients with cardiovascular comorbidities? (Sponsored by Astellas Pharma) Break / Exhibition / E-poster Viewing British Cardio-Oncology Society @HKC Cardio-oncology in the Era of COVID-Best practice for Cardio-oncology patients in the era of COVID-19: Vaccine, treatment, tele-health and more	Dr. Daniel Knight  Dr. Pui- shan Chan  CC ASC: 19 Pandemic Prof. Stuart Rosen
1430-1630	Lunch Symposium  How does innovation transform the way we treat LDL-C in patients with ASCVD? (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Card Intervention Cases Presentation	Ray acc	1430-1500 1430-1500 1530-1600 1600-1805	Cardiovascular Diseases  Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen) How shall we manage hyperuricaemia in patients with cardiovascular comorbidities? (Sponsored by Astellas Pharma) Break / Exhibition / E-poster Viewing British Cardio-Oncology Society @HKC Cardio-oncology in the Era of COVID- Best practice for Cardio-oncology patients in the era of COVID-19: Vaccine, treatment, tele-health and more Importance of drug interactions for cardio-oncology patients	Dr. Daniel Knight  Dr. Pui- shan Chan  CC ASC: 19 Pandemic Prof. Stuart Rosen  Dr. Ka-on Lam
<b>1430-1630</b> 1630-1650	Lunch Symposium How does innovation transform the way we treat LDL-C in patients with ASCVD? (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Card Intervention Cases Presentation  Break / Exhibition / E-poster Viewing Best HKCC-HKPHCA Challenging/I	Ray	1400-1430 1430-1500 1530-1600 1600-1805 1600-1625	Cardiovascular Diseases Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen) How shall we manage hyperuricaemia in patients with cardiovascular comorbidities? (Sponsored by Astellas Pharma) Break / Exhibition / E-poster Viewing British Cardio-Oncology Society @HKC Cardio-oncology in the Era of COVID- Best practice for Cardio-oncology patients in the era of COVID-19: Vaccine, treatment, tele-health and more Importance of drug interactions for cardio-oncology patients with coronary artery Oncology patients with coronary artery	Dr. Daniel Knight  Dr. Pui- shan Chan  CC ASC: 19 Pandemic Prof. Stuart Rosen  Dr. Ka-on Lam
<b>1430-1630</b> 1630-1650	Lunch Symposium How does innovation transform the way we treat LDL-C in patients with ASCVD? (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Card Intervention Cases Presentation  Break / Exhibition / E-poster Viewing	Ray	1400-1430 1430-1500 1530-1600 1600-1805 1600-1625	Cardiovascular Diseases Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen). How shall we manage hyperuricaemia in patients with cardiovascular comorbidities? (Sponsored by Astellas Pharma) Break / Exhibition / E-poster Viewing British Cardio-Oncology Society @HKC Cardio-oncology in the Era of COVID-Best practice for Cardio-oncology patients in the era of COVID-19: Vaccine, treatment, tele-health and more Importance of drug interactions for cardio-oncology patients Oncology patients with coronary artery diseases and percutaneous coronary	Dr. Daniel Knight  Dr. Pui- shan Chan  CC ASC: 19 Pandemic Prof. Stuart Rosen  Dr. Ka-on Lam Dr. Yu-ho
<b>1430-1630</b> 1630-1650	Lunch Symposium How does innovation transform the way we treat LDL-C in patients with ASCVD? (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Card Intervention Cases Presentation  Break / Exhibition / E-poster Viewing Best HKCC-HKPHCA Challenging/I	Ray	1430-1430 1430-1500 1530-1600 1600-1805 1600-1625 1625-1650 1650-1715	Cardiovascular Diseases Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen) How shall we manage hyperuricaemia in patients with cardiovascular comorbidities? (Sponsored by Astellas Pharma) Break / Exhibition / E-poster Viewing British Cardio-Oncology Society @HKC Cardio-oncology in the Era of COVID- Best practice for Cardio-oncology patients in the era of COVID-19: Vaccine, treatment, tele-health and more Importance of drug interactions for cardio-oncology patients Oncology patients with coronary artery diseases and percutaneous coronary intervention-a special population	Dr. Daniel Knight  Dr. Pui- shan Chan  CC ASC: 19 Pandemic Prof. Stuart Rosen  Dr. Ka-on Lam Dr. Yu-ho Chan
<b>1430-1630</b> 1630-1650	Lunch Symposium How does innovation transform the way we treat LDL-C in patients with ASCVD? (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Card Intervention Cases Presentation  Break / Exhibition / E-poster Viewing Best HKCC-HKPHCA Challenging/I	Ray	1400-1430 1430-1500 1530-1600 1600-1805 1600-1625	Cardiovascular Diseases Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen) How shall we manage hyperuricaemia in patients with cardiovascular comorbidities? (Sponsored by Astellas Pharma) Break / Exhibition / E-poster Viewing British Cardio-Oncology Society @HKC Cardio-oncology in the Era of COVID-Best practice for Cardio-oncology patients in the era of COVID-19: Vaccine, treatment, tele-health and more Importance of drug interactions for cardio-oncology patients Oncology patients Oncology patients with coronary artery diseases and percutaneous coronary intervention-a special population Role of cardiac imaging for early	Dr. Daniel Knight  Dr. Pui- shan Chan  CC ASC: 19 Pandemic Prof. Stuart Rosen Dr. Ka-on Lam Dr. Yu-ho Chan  Dr. Chris
<b>1430-1630</b> 1630-1650	Lunch Symposium How does innovation transform the way we treat LDL-C in patients with ASCVD? (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Card Intervention Cases Presentation  Break / Exhibition / E-poster Viewing Best HKCC-HKPHCA Challenging/I	Ray	1430-1430 1430-1500 1530-1600 1600-1805 1600-1625 1625-1650 1650-1715	Cardiovascular Diseases Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen) How shall we manage hyperuricaemia in patients with cardiovascular comorbidities? (Sponsored by Astellas Pharma) Break / Exhibition / E-poster Viewing British Cardio-Oncology Society @HKC Cardio-oncology in the Era of COVID-19. Vaccine, treatment, tele-health and more Importance of drug interactions for cardio-oncology patients with coronary artery diseases and percutaneous coronary intervention-a special population Role of cardiac imaging for early recognition and treatment of	Dr. Daniel Knight  Dr. Pui- shan Chan  CC ASC: 19 Pandemic Prof. Stuart Rosen  Dr. Ka-on Lam Dr. Yu-ho Chan
<b>1430-1630</b> 1630-1650	Lunch Symposium How does innovation transform the way we treat LDL-C in patients with ASCVD? (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Card Intervention Cases Presentation  Break / Exhibition / E-poster Viewing Best HKCC-HKPHCA Challenging/I	Ray	1430-1430 1430-1500 1530-1600 1600-1805 1600-1625 1625-1650 1650-1715	Cardiovascular Diseases Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen). How shall we manage hyperuricaemia in patients with cardiovascular comorbidities? (Sponsored by Astellas Pharma) Break / Exhibition / E-poster Viewing British Cardio-Oncology Society @HKC Cardio-oncology in the Era of COVID-Best practice for Cardio-oncology patients in the era of COVID-19: Vaccine, treatment, tele-health and more Importance of drug interactions for cardio-oncology patients Oncology patients with coronary artery diseases and percutaneous coronary intervention-a special population Role of cardiac imaging for early recognition and treatment of cardiomyopathy related to cancer	Dr. Daniel Knight  Dr. Pui- shan Chan  CC ASC: 19 Pandemic Prof. Stuart Rosen Dr. Ka-on Lam Dr. Yu-ho Chan  Dr. Chris
<b>1430-1630</b> 1630-1650	Lunch Symposium How does innovation transform the way we treat LDL-C in patients with ASCVD? (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Card Intervention Cases Presentation  Break / Exhibition / E-poster Viewing Best HKCC-HKPHCA Challenging/I	Ray	1400-1430 1430-1500 1530-1600 1600-1805 1600-1625 1625-1650 1650-1715	Cardiovascular Diseases Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen) How shall we manage hyperuricaemia in patients with cardiovascular comorbidities? (Sponsored by Astellas Pharma) Break / Exhibition / E-poster Viewing British Cardio-Oncology Society @HKC Cardio-oncology in the Era of COVID-Best practice for Cardio-oncology patients in the era of COVID-19: Vaccine, treatment, tele-health and more Importance of drug interactions for cardio-oncology patients Oncology patients with coronary artery diseases and percutaneous coronary intervention-a special population Role of cardiac imaging for early recognition and treatment of cardiomyopathy related to cancer treatments	Dr. Daniel Knight  Dr. Pui- shan Chan  CC ASC: 19 Pandemic Prof. Stuart Rosen  Dr. Ka-on Lam Dr. Yu-ho Chan  Dr. Chris Plummer
<b>1430-1630</b> 1630-1650	Lunch Symposium How does innovation transform the way we treat LDL-C in patients with ASCVD? (Sponsored by Novartis Pharmaceuticals)  Best Challenging/Interesting Card Intervention Cases Presentation  Break / Exhibition / E-poster Viewing Best HKCC-HKPHCA Challenging/I	Ray	1430-1430 1430-1500 1530-1600 1600-1805 1600-1625 1625-1650 1650-1715	Cardiovascular Diseases Holistic pulmonary arterial hypertension management - Best practice from a pulmonary hypertension centre (Sponsored by Johnson & Johnson Janssen). How shall we manage hyperuricaemia in patients with cardiovascular comorbidities? (Sponsored by Astellas Pharma) Break / Exhibition / E-poster Viewing British Cardio-Oncology Society @HKC Cardio-oncology in the Era of COVID-Best practice for Cardio-oncology patients in the era of COVID-19: Vaccine, treatment, tele-health and more Importance of drug interactions for cardio-oncology patients Oncology patients with coronary artery diseases and percutaneous coronary intervention-a special population Role of cardiac imaging for early recognition and treatment of cardiomyopathy related to cancer	Dr. Daniel Knight  Dr. Pui- shan Chan  CC ASC: 19 Pandemic Prof. Stuart Rosen Dr. Ka-on Lam Dr. Yu-ho Chan  Dr. Chris



#### **Cardiac Manifestations of COVID-19**

### 9 July 2022 (Saturday)

Time	Session / Topic / Speaker		
1000-1100	Session I Chairpersons: Ms. Amy Chung-ying Chan, Mr. Man-pan Li, Dr. Jonathan G Sung		
1000-1030	Clinical considerations of using oral antiviral drugs for the treatment of COVID-19	Hon. A. Prof. William Chun-ming Chui	
1030-1100	COVID-19: Cardiac manifestations in adults	Dr. David Ka-yip Lo	
1100-1130	Break / Exhibition / E-poster Viewing		
1130-1230	Session II Chairpersons: Ms. Camille Kam-tak Ho, Dr. Sunny Chun-fung Tsang, Prof. Thomas Kwok-shing Wong		
1130-1200	Nursing diary for care of myocarditis patients: From acute to home	Ms. Mei-yi Chau	
1200-1230	Post myocarditis heart failure treatment: From lifestyle modification to device therapy	Dr. Chi-yui Yung	

Program is subject to change without prior notice.

#### **Symposium Co-joint Organizers**



香港心臟護理學會有限公司 Hong Kong Cardiac Nursing Association Ltd.



香港心臟護士專科學院有限公司 Hong Kong College of Cardiac Nursing Ltd.



香港醫院藥劑師學會 The Society of Hospital Pharmacists of Hong Kong

#### **Symposium Organizing Committee**

Dr. Andy Wai-kwong Chan

Ms. Sin-hing Chiu

Hon. A. Prof. William Chun-ming Chui

Ms. Jackie Shuk-ling Kan

Ms. Carmen Yeuk-yan Lai

Dr. David Ka-yip Lo

# PAEDIATRIC CARDIOLOGY PROGRAM

## 9 July 2022 (Saturday)

Time	Session / Topic / Speaker		
0825-0830	Welcome Address	Dr. Tak-cheung Yung	
0830-1030	Paediatric Cardiology Symposium I	1 2 2 2 3 3	
0830-0850	Anatomy and physiology of the lymphatic system	Dr. David Matthew Biko	
0850-0900	Q&A		
0900-0920	Modern imaging technique for the lymphatic system - MR lymphangiography	Dr. David Matthew Biko	
0920-0930	Q&A		
0930-0950	My lymphatic intervention algorithm: How I improve outcome	Dr. Yoav Dori	
0950-1000	Q&A		
1000-1030	Case discussion - Management of central lymphatic flow disorder in TGA patients post-arterial switch	Dr. David Matthew Biko, Dr. Yoav Dori and other panellists	
1030-1100	Break / Exhibition / E-poster Viewing		
1100-1300	Free Paper Session (Abstract & Interesting Case Presentations)		
	Abstract Presentation		
	Case Presentation		
1300-1400	Lunch Break		
1415-1615	Paediatric Cardiology Symposium II		
1415-1435	Lymphatic intervention to lymph medicine: Part 1 - How I started a lymphatic service	Prof. Saebeom Hur	
1435-1445	Q&A		
1445-1505	Lymphatic intervention to lymph medicine: Part 2 - Why understanding pathophysiology of lymphatic disease is crucial?	Prof. Saebeom Hur	
1505-1515	Q&A		
1515-1535	Practical tips for success in lymphatic intervention: Lymphangiography, thoracic duct cannulation, DCMRL	Prof. Saebeom Hur	
1535-1545	Q&A		
1545-1615	Q&A and Panel Discussion / Case Discussion	Prof. Saebeom Hur and other panellists	
1615-1620	Closing Remarks	Dr. Kin-shing Lun	
1630-1800	Adult Congenital Heart Disease (ACHD) Symposium		
1630-1650	Aortic stenting in ACHD patients: Special considerations and how to mitigate risk	Dr. Kothandam Sivakumar	
1650-1710	Percutaneous pulmonary valve Implantation: Development & way forward	Dr. Robin Hay-son Chen	
1710-1730	Transcatheter tricuspid valve repair: Feasibility & challenges in ACHD	Dr. Simon Cheung-chi Lam	
1730-1750	Transcatheter closure of sinus venosus ASD: What? Who? How?	Sir Prof. Shakeel Qureshi	
1750-1800	Q&A		

Program is subject to change without prior notice.

# CARDIOLOGY COURSE FOR FAMILY PHYSICIANS AND GENERAL PRACTITIONERS

## 10 July 2022 (Sunday)

Time	Session / Topic / Speaker	
0900-1030	Session 1 - Preventive Cardiology: Expanding the Role of GP in	Cardiology
0900-0930	Managing patients on aspirin for 1° and 2° prevention	Dr. Danny Hoi-fan Chow
0930-1000	Cardiovascular disease prevention by diet modification	Dr. Jason Kwok-chun Ko
1000-1030	Use of high-intensity statins in primary care setting and in secondary prevention (Sponsored by Viatris Healthcare)	Dr. Andrew Kei-yan Ng
1030-1100	Break / Exhibition / E-poster Viewing	
1100-1230	Session 2 - Cardiology Updates: New Guidelines in Clinical Prac	ctice
1100-1130	What primary care providers should know about cardiac pacing in 2022?	Dr. Jacky Kit Chan
1130-1200	Evolution of HF management: Making sense of latest ESC & ACC guidelines	Dr. Elaine Mo-chee Chau
1200-1230	Approach to chest pain evaluation	Dr. Yuk-kong Lau
1230-1400	Lunch Break	
1400-1530	Session 3 - Common Cardiology Challenges in General Practic	e
1400-1430	"De-escalation" of antiplatelet therapy in high bleeding risk patients	Dr. Alan Ka-chun Chan
1430-1500	Incorporating SGLT2i in clinical practice for CV and renal risk reduction	Dr. Thomas Tunggal
1500-1530	Novel strategies to achieve lipid goals	Dr. Frankie Chor-cheung Tam
1530-1600	Break / Exhibition / E-poster Viewing	
1600-1700	Session 4 - Cardiology Issues in Women & Paediatrics	
1600-1615	Heart failure in women: Causes, consequence and management	Dr. Michael Ka-lam Wong
1615-1630	Hypertension in women: Risk factors, monitoring and treatment	Dr. Raymond Chi-yan Fung
1630-1645	Clinical approach to palpitations and syncope in paediatric patients	Dr. Sit-yee Kwok
1645-1700	Clinical approach to chest pain in paediatric patients	Dr. Kwok-chiu Chan

Program is subject to change without prior notice.

# CARDIOVASCULAR THERAPEUTICS WORKSHOP

## 10 July 2022 (Sunday)

	Room \$426-427			
Time	Session & Topic	Speaker		
0900-1000	Workshop 1 - OCT-Supported PCI for Calcified Lesions* (Sponsored by Abbott Medical)	TBC		
1000-1100	Break			
	Workshop 2 - How to Overcome Challenges in Micra Implantation?* (Sponsored by Medtronic)			
	Welcome			
1100-1200	Case 1 - Catheter manipulation tips and tricks Panel Discussion	Dr. Ling-ling Ip		
	Case 2 - Micra snaring technique Panel Discussion	Dr. Yuet-wong Cheng		
	Case 3 - Echo guided micra implantation Panel Discussion	Dr. Michael Ka-lam Wong		
	Closing			

	Room S428			
Time	Session & Topic	Speaker		
1000-1230	Workshop 3 - Percutaneous Mechanical Circulatory Support* (Sponsored by ABIOMED)	TBC		

<sup>\*</sup> For physical participants only.

Program is subject to change without prior notice.

#### **PROGRAM HIGHLIGHTS**

- ACC@HKCC ASC: Hot Issues in Cardiology
- APSC@HKCC ASC: Advances in Coronary Intervention
- BCOS@HKCC ASC: Cardio-oncology in the Era of COVID-19 Pandemic
- ESC@ HKCC ASC: Controversies in the Management of Coronary Artery
  Disease
- KSC@HKCC ASC: Advances in Pacing and Cardiac Electrophysiology
- · Hong Kong Heart Foundation Lecture
- HKCC 30<sup>th</sup> Anniversary Keynote Lecture cum Presidential Forum
- Hong Kong Heart Foundation, Dr CO Pun and Dr Mary BL Kwong Scholarship Symposium
- · Heart Rhythm Symposium
- · Heart Failure Symposium
- · Diabetes and Cardiovascular Risk Factors Symposium
- Coronary Ischaemia Symposium
- Atrial Fibrillation Symposium
- Symposium on Under-recognized Aspects in Cardiovascular Diseases
- Guidelines and Practice: Clinical Case Based Conference (GAP-CCBC)
- Allied Cardiovascular Health Professionals Symposium: Cardiac Manifestations of COVID-19
- · Paediatric Cardiology Program
- · Adult Congenital Heart Disease Symposium
- · Cardiology Course for Family Physicians and General Practitioners
- Cardiovascular Therapeutics Workshop
- Challenging/Interesting Clinical Cardiology Cases Presentation
- Challenging/Interesting Cardiac Intervention Cases Presentation
- · Abstracts and Poster Presentation

#### ACCREDITATION (CME/CNE)

Application is in progress. Details of accreditation will be announced later on the Congress website.

#### **ACKNOWLEDGEMENT**

A. Menarini Hong Kong Ltd. Abbott Medical (Hong Kong) Limited ABIOMED

Amgen Hong Kong Limited

Astellas Pharma Hong Kong Company Limited

AstraZeneca Hong Kong Limited

Bayer HealthCare Limited

BGI Tech Solutions (Hong Kong) Co., Ltd. Biosensors Intervention Technologies HK Limited

Boehringer Ingelheim (Hong Kong) Limited

Butterfly Network Inc.

Cardioscan (HK) Service Ltd.

Daiichi Sankyo Hong Kong Limited

Eli Lilly Asia, Inc.

Elixir Medical Corporation

Hong Kong Heart Foundation Limited

Johnson & Johnson (Hong Kong) Ltd.

Lee's Pharmaceutical (HK) Ltd. Medtronic Hong Kong Medical Ltd.

Merck Pharmaceutical (Hong Kong) Limited

Novartis Pharmaceuticals (HK) Limited

Novo Nordisk Hong Kong Limited

OrbusNeich Medical Co. Ltd.

Organon Hong Kong Limited

Otsuka Pharmaceutical (H.K.) Ltd.

Pacific Medical Systems Limited

Pfizer Corporation Hong Kong Limited

Prism Technologies Limited

Roche Diagnostics (Hong Kong) Limited

Sanofi Hong Kong Limited

Servier Hong Kong Limited

Viatris Healthcare Hong Kong Limited

Zuellia Pharma

#### **SUPPORTING ORGANIZATIONS** (As of 15 June 2022)





香港心臟護士專科學院有限公司 Hong Kong College of Cardiac Nursing Ltd





#### **CONTACT US**

HKCC ASC 2022 Congress Secretariat c/o International Conference Consultants Ltd. Unit C-D, 17/F, Max Share Centre, 373 King's Road, North Point, Hong Kong Tel: (852) 2559 9973 Fax: (852) 2547 9528 Email: info@hkcasc.com